1. Home
  2. INTS vs AKTX Comparison

INTS vs AKTX Comparison

Compare INTS & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • AKTX
  • Stock Information
  • Founded
  • INTS 2012
  • AKTX N/A
  • Country
  • INTS United States
  • AKTX United States
  • Employees
  • INTS N/A
  • AKTX N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • AKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • INTS Health Care
  • AKTX Health Care
  • Exchange
  • INTS Nasdaq
  • AKTX Nasdaq
  • Market Cap
  • INTS 33.4M
  • AKTX 32.8M
  • IPO Year
  • INTS 2023
  • AKTX N/A
  • Fundamental
  • Price
  • INTS $2.11
  • AKTX $1.08
  • Analyst Decision
  • INTS Strong Buy
  • AKTX
  • Analyst Count
  • INTS 3
  • AKTX 0
  • Target Price
  • INTS $8.50
  • AKTX N/A
  • AVG Volume (30 Days)
  • INTS 28.4K
  • AKTX 27.7K
  • Earning Date
  • INTS 03-13-2025
  • AKTX 02-24-2025
  • Dividend Yield
  • INTS N/A
  • AKTX N/A
  • EPS Growth
  • INTS N/A
  • AKTX N/A
  • EPS
  • INTS N/A
  • AKTX N/A
  • Revenue
  • INTS N/A
  • AKTX N/A
  • Revenue This Year
  • INTS N/A
  • AKTX N/A
  • Revenue Next Year
  • INTS N/A
  • AKTX N/A
  • P/E Ratio
  • INTS N/A
  • AKTX N/A
  • Revenue Growth
  • INTS N/A
  • AKTX N/A
  • 52 Week Low
  • INTS $1.50
  • AKTX $0.90
  • 52 Week High
  • INTS $5.94
  • AKTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • INTS 41.98
  • AKTX 43.34
  • Support Level
  • INTS $1.84
  • AKTX $1.10
  • Resistance Level
  • INTS $2.53
  • AKTX $1.33
  • Average True Range (ATR)
  • INTS 0.32
  • AKTX 0.15
  • MACD
  • INTS -0.02
  • AKTX -0.01
  • Stochastic Oscillator
  • INTS 37.50
  • AKTX 5.97

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Share on Social Networks: